Relapsed and Refractory Myeloma Case 2 James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Relapsed/Refractory…

Management of Older Patients Not Eligible For Transplant Induction Therapy For Multiple Myeloma: Two vs Three Drug Regimen and Role of Risk Stratification Ravi Vij MD Associate…

PowerPoint Presentation Update on transplant-ineligible patients: Which regimens are best? Suzanne Lentzsch MD, PhD Columbia University, New York 1 Disclosures for Suzanne…

* ANCO ASH Highlights 2007: Multiple Myeloma Joseph M. Tuscano, MD University of California, Davis * Abstracts [73] Bortezomib (Velcade )-Thalidomide-Dexamethasone (VTD)…

Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Multiple Myeloma Friday, December 6, 2013 6:30 PM - 9:00 PM New Orleans,…

Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression-Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A…

Management of Older Patients Not Eligible For Transplant Induction Therapy For Multiple Myeloma: Two vs Three Drug Regimen and Role of Risk Stratification Ravi Vij MD Associate…

original article T h e n e w e ngl a nd j o u r na l o f m e dic i n e n engl j med 371;10 nejm.org september 4, 2014906 Lenalidomide and Dexamethasone in Transplant-Ineligible…

Kenneth C Anderson, MD Kraft Family Professor of Medicine, Harvard Medical School Chief, Division of Hematologic Neoplasia Director, Jerome Lipper Multiple Myeloma Center…